Monopar Therapeutics Inc.
MNPR
$113.04
$2.632.38%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 52.04% | 75.01% | 115.49% | 99.02% | 58.61% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.77% | 5.93% | 3.36% | 208.95% | 155.07% |
| Operating Income | -15.77% | -5.93% | -3.36% | -208.95% | -155.07% |
| Income Before Tax | -3.10% | 9.57% | 11.99% | -200.27% | -142.96% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.10% | 9.57% | 11.99% | -200.27% | -142.96% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.10% | 9.57% | 11.99% | -200.27% | -142.96% |
| EBIT | -15.77% | -5.93% | -3.36% | -208.95% | -155.07% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 34.74% | 45.20% | 49.52% | -72.45% | -43.66% |
| Normalized Basic EPS | 34.74% | 45.19% | 49.52% | -72.44% | -43.67% |
| EPS Diluted | 34.74% | 45.20% | 49.52% | -72.45% | -43.66% |
| Normalized Diluted EPS | 34.74% | 45.19% | 49.52% | -72.44% | -43.67% |
| Average Basic Shares Outstanding | 46.08% | 64.91% | 96.02% | 97.85% | 79.98% |
| Average Diluted Shares Outstanding | 46.08% | 64.91% | 96.02% | 97.85% | 79.98% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |